It’s no secret that while biosimilar medicines are gradually consolidating their presence in the Europe pharmaceutical market, their use varies widely by molecule and by country, and often within the same country, depending on factors such as doctor incentives, purchasing and reimbursement policies, and the perceptions of healthcare professionals and patients that are often swayed by misinformation on the safety of biosimilars.
Speakers from several European countries outlined their experiences with biosimilars to date at Medicines For Europe’s 17th biosimilars conference, which...